Sugi Predict

Sugi Predict / Compounds / SCHEMBL1309315

SCHEMBL1309315

SCHEMBL1309315

CC(C)c1ccc2nc(N)sc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 4/20 1.00
▸ SMN1; SMN2 Q16637 3/20 1.00
▸ NPC1 O15118 3/20 1.00
▸ SCN4A P35499 2/20 1.00
▸ MAPT P10636 1/20 0.61
▸ AXL P30530 1/20 0.56
▸ GFER P55789 1/20 0.56
▸ GAA P10253 1/20 0.56
▸ HTT P42858 1/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ CYP3A4 P08684 4/20 0.56
▸ CYP1A2 P05177 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ PI4KA P42356 6/20 0.51
▸ PI4KB Q9UBF8 6/20 0.51
▸ PIK3CA P42336 5/20 0.51
▸ ALDH1A1 P00352 4/20 0.51
▸ HSD17B10 Q99714 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ EPHX2 P34913 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18879306 0.86 RAB9A (0.76) RAB9ASMN1; SMN2NPC1SCN4AMAPT
SCHEMBL8122351 0.86 RAB9A (0.76) RAB9ASMN1; SMN2NPC1SCN4AMAPT
SCHEMBL13533137 0.86 RAB9A (0.75) RAB9ASMN1; SMN2NPC1SCN4AMAPT
SCHEMBL19216330 0.83 RAB9A (0.71) RAB9ASMN1; SMN2NPC1SCN4AMAPT
SCHEMBL27527540 0.82 RAB9A (0.69) RAB9ASMN1; SMN2NPC1SCN4AMAPT
SCHEMBL10508844 0.82 RAB9A (0.69) RAB9ASMN1; SMN2NPC1SCN4AMAPT
SCHEMBL21709939 0.82 RAB9A (0.69) RAB9ASMN1; SMN2NPC1SCN4AMAPT
SCHEMBL74053 0.81 RAB9A (0.68) RAB9ASMN1; SMN2NPC1SCN4AMAPT
SCHEMBL15887354 0.81 RAB9A (0.68) RAB9ASMN1; SMN2NPC1SCN4AMAPT
SCHEMBL798519 0.80 RAB9A (0.67) RAB9ASMN1; SMN2NPC1SCN4AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3758697-B1 NOVEL ANTIMYCOBACTERIAL HETEROCYCLIC AMIDES CRESTONE INC (US) 2024-10-16 — — EP claimed
CN-118772080-A Antimycobacterial heterocyclic amides 克莱斯通公司 2024-10-15 — — CN claimed
CN-112423746-B Novel antimycobacterial heterocyclic amides 克莱斯通公司 2024-06-28 — — CN claimed
EP-3827665-B1 MAMMAL KINASE INHIBITORS TO PROMOTE IN VITRO EMBRYOGENESIS INDUCTION OF PLANTS CONSEJO SUPERIOR INVESTIGACION (ES) 2025-02-19 — — EP disclosed
CN-118772080-A Antimycobacterial heterocyclic amides 克莱斯通公司 2024-10-15 — — CN disclosed
US-12091407-B2 Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof VTV THERAPEUTICS LLC (US) 2024-09-17 — — US disclosed
US-12030853-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2024-07-09 — — US disclosed
CN-112423746-B Novel antimycobacterial heterocyclic amides 克莱斯通公司 2024-06-28 — — CN disclosed
US-11912678-B2 LRRK2 inhibiting compounds and use thereof for treating neurodegenerative diseases CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) 2024-02-27 — — US disclosed
US-20230312548-A1 SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF VTV THERAPEUTICS LLC 2023-10-05 — — US disclosed
US-20230286970-A1 NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS ITALFARMACO SPA (IT) 2023-09-14 — — US disclosed
WO-2005070920-A1 AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-08-04 — — WO disclosed
WO-2004098494-A2 COMPOUNDS, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2004-11-18 — — WO disclosed
EP-0282971-B1 Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents WARNER LAMBERT CO (US) 1994-12-28 — — EP disclosed
US-4997918-A Benzthiazolium azo dyes CIBA-GEIGY CORPORATION (US) 1991-03-05 — — US disclosed
US-4971983-A Use as anesthetics in surgery where a risk of cerebrovascular damage exists; e.g. riluzole WARNER-LAMBERT COMPANY (US) 1990-11-20 — — US disclosed
US-4918090-A ADMINISTERING TO STROKE PATIENT WARNER-LAMBERT COMPANY (US) 1990-04-17 — — US disclosed
US-4826860-A STROKES WARNER-LAMBERT COMPANY (US) 1989-05-02 — — US disclosed
EP-0282971-A2 Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents WARNER-LAMBERT COMPANY (US) 1988-09-21 — — EP disclosed
EP-0105031-A2 Cationic azo dyestuffs CIBA-GEIGY AG (CH) 1984-04-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12091407-B2 Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof GLS, HMOX2, REN RAB9A 1694/4885SMN1; SMN2 3632/4885NPC1 1071/4885
US-20230312548-A1 SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF GLS, HMOX2, REN RAB9A 1800/4885SMN1; SMN2 3147/4885NPC1 1492/4885
US-20230286970-A1 NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS HDAC6, HDAC1, HDAC3 RAB9A 3395/4885SMN1; SMN2 2068/4885NPC1 3167/4885
US-11912678-B2 LRRK2 inhibiting compounds and use thereof for treating neurodegenerative diseases LRRK2, PARK7, SNCA RAB9A 815/4885SMN1; SMN2 293/4885NPC1 550/4885
US-12030853-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 RAB9A 2027/4885SMN1; SMN2 1476/4885NPC1 2354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.